Using lesion swap specimen and real-time reverse transcription polymerase chain reaction (RT-PCR) testing, the new product will identify Monkeypox, as recommended by the Centers for Disease Control and Prevention (CDC ).
RT-PCR is used when the initial material is RNA, which is first transcribed into complementary DNA (cDNA) by reverse transcriptase, in this process.
The cDNA is then later used as the template for the polymerase chain reaction.
Various benefits of the new diagnostic testing product include the delivery of rapid test results, a simple collection method using a skin lesion swab, and positive/negative report formats that are easy to read.
US BioTek Laboratories CEO Jack Frausing said: “As we have seen in recent years, quantifying our viral statuses as quickly as possible can have huge impacts on our personal and public health.
“At US BioTek, we strive to offer our customers the testing they need to improve the lives of their patients. In the case of Monkeypox, we are doing so by offering test results in less than 24 hours.”
US BioTek is offering Monkeypox diagnostic testing to all practitioners with its accounts.
An international laboratory, the company is involved in the development of testing methods to deliver quality results with accuracy.
It uses third-party, peer-reviewed literature, as well as insights from its network of providers for the development of evidence-based panels tailored for clinical applications.
This process helped the laboratory to create comprehensive testing options for providers, in addition to delivering the needed tools to take health decisions.